| NCT07157514 | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML | NOT_YET_RECRUITING | PHASE2, PHASE3 | 2026-01 | 2034-02 | 2029-02 |
| NCT03932318 | Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | WITHDRAWN | PHASE1, PHASE2 | 2023-03 | 2024-09 | 2023-12 |
| NCT03867682 | Venetoclax and Lintuzumab-Ac225 in AML Patients | UNKNOWN | PHASE1, PHASE2 | 2020-01-15 | 2024-06 | 2023-11 |
| NCT02998047 | A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma | TERMINATED | PHASE1 | 2016-12 | 2020-05 | 2020-05 |
| NCT02665065 | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | PHASE3 | 2016-06 | 2026-12 | 2022-06 |
| NCT02575963 | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | COMPLETED | PHASE1, PHASE2 | 2012-10 | 2020-05 | 2018-11 |